ANEW Medical shares are trading higher after the company announced that is has been granted and issued a patent in Europe, EP3377091B1, for the use of its Klotho gene sequence and gene delivery systems for the treatment of diminished cognition, memory loss, dementia and other neurodegenerative diseases.
Portfolio Pulse from Benzinga Newsdesk
ANEW Medical shares are trading higher after the company announced it has been granted a European patent for its Klotho gene sequence and gene delivery systems for treating neurodegenerative diseases.
June 26, 2024 | 11:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ANEW Medical shares are trading higher following the announcement of a European patent for its Klotho gene sequence and gene delivery systems, which target neurodegenerative diseases.
The granting of a European patent is a significant milestone for ANEW Medical, as it validates the company's technology and opens up new market opportunities in Europe. This positive development is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100